Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer - final analysis from the phase II PACIFIC-6 trial
Background - Durvalumab after concurrent chemoradiotherapy (cCRT) is the standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). However, patients often receive sequential chemoradiotherapy (sCRT) due to factors including advanced age or frailty, comorbidities,...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 2025
|
| In: |
ESMO open
Year: 2025, Jahrgang: 10, Heft: 6, Pages: 1-9 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2025.105071 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2025.105071 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702925009408 
|
| Verfasserangaben: | M.C. Garassino, J. Khalifa, M. Reck, C. Chouaid, H. Bischoff, N. Reinmuth, L. Cove-Smith, T. Mansy, D.L. Cortinovis, M.R. Migliorino, A. Delmonte, J. Garcia Sánchez, L.E. Chara Velarde, R. Bernabe, L. Paz-Ares, P. Chander, I. Diaz Perez, K. Foroutanpour, U. Emeribe & C. Faivre-Finn |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1936696878 | ||
| 003 | DE-627 | ||
| 005 | 20250924113946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250924s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2025.105071 |2 doi | |
| 035 | |a (DE-627)1936696878 | ||
| 035 | |a (DE-599)KXP1936696878 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Garassino, Marina |e VerfasserIn |0 (DE-588)1220527238 |0 (DE-627)1737458330 |4 aut | |
| 245 | 1 | 0 | |a Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer - final analysis from the phase II PACIFIC-6 trial |c M.C. Garassino, J. Khalifa, M. Reck, C. Chouaid, H. Bischoff, N. Reinmuth, L. Cove-Smith, T. Mansy, D.L. Cortinovis, M.R. Migliorino, A. Delmonte, J. Garcia Sánchez, L.E. Chara Velarde, R. Bernabe, L. Paz-Ares, P. Chander, I. Diaz Perez, K. Foroutanpour, U. Emeribe & C. Faivre-Finn |
| 264 | 1 | |c June 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 27. Mai 2025 | ||
| 500 | |a Gesehen am 24.09.2025 | ||
| 520 | |a Background - Durvalumab after concurrent chemoradiotherapy (cCRT) is the standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). However, patients often receive sequential chemoradiotherapy (sCRT) due to factors including advanced age or frailty, comorbidities, or disease- or access-related concerns. The phase II PACIFIC-6 trial (NCT03693300) evaluated the safety of durvalumab after sCRT in this setting. Interim results indicated a similar safety profile to that observed with durvalumab after cCRT, with encouraging preliminary efficacy. We report outcomes from the final analysis. - Patients and methods - Adults with unresectable, stage III NSCLC, Eastern Cooperative Oncology Group performance status ≤2, and no disease progression following platinum-based sCRT were enrolled to receive durvalumab 1500 mg intravenously once every 4 weeks for up to 24 months. The primary endpoint was the incidence of grade 3/4 adverse events (AEs) possibly related to treatment (PRAEs) occurring within 6 months. Secondary endpoints included overall survival (OS) and progression-free survival (PFS; investigator assessed as per RECIST v1.1). - Results - As of 20 March 2023, 117 patients (65.8% aged ≥65 years; 98.3% with past or present comorbidities) were enrolled. Overall, 27.4% of patients had grade 3/4 AEs and 6.0% had grade 3/4 PRAEs, including two patients (1.7%) with pneumonitis. Three patients (2.6%) had fatal AEs, with one (0.9%) having a fatal PRAE (pneumonitis). Overall, 27.4% discontinued durvalumab due to AEs. Median follow-up was 32.6 and 30.2 months among patients censored for OS and PFS, respectively. Median OS was 39.0 months [95% confidence interval (CI) 30.6 months-not calculable]; 3-year OS rate was 56.5% (95% CI 46.4% to 65.5%). Median PFS was 13.1 months (95% CI 7.4-19.9 months); 2-year PFS rate was 35.3% (95% CI 26.5% to 44.3%). - Conclusions - Durvalumab after sCRT was well tolerated and could be an alternative treatment strategy when cCRT is not feasible. Confirmatory randomized phase III data are awaited. | ||
| 650 | 4 | |a durvalumab | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a locally advanced NSCLC | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a sequential chemoradiotherapy | |
| 700 | 1 | |a Khalifa, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reck, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chouaid, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 700 | 1 | |a Reinmuth, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cove-Smith, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mansy, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortinovis, D. L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Migliorino, M. R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delmonte, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garcia Sánchez, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chara Velarde, L. E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bernabe, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paz-Ares, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chander, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Diaz Perez, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Foroutanpour, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Emeribe, U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Faivre-Finn, C. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 10(2025), 6 vom: Juni, Artikel-ID 105071, Seite 1-9 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer - final analysis from the phase II PACIFIC-6 trial |
| 773 | 1 | 8 | |g volume:10 |g year:2025 |g number:6 |g month:06 |g elocationid:105071 |g pages:1-9 |g extent:9 |a Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer - final analysis from the phase II PACIFIC-6 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2025.105071 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702925009408 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250924 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |e 50000PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1936696878 |e 4775745093 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer - final analysis from the phase II PACIFIC-6 trial","title_sort":"Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer - final analysis from the phase II PACIFIC-6 trial"}],"person":[{"given":"Marina","roleDisplay":"VerfasserIn","display":"Garassino, Marina","family":"Garassino","role":"aut"},{"role":"aut","family":"Khalifa","given":"J.","roleDisplay":"VerfasserIn","display":"Khalifa, J."},{"role":"aut","family":"Reck","roleDisplay":"VerfasserIn","display":"Reck, M.","given":"M."},{"role":"aut","family":"Chouaid","given":"C.","roleDisplay":"VerfasserIn","display":"Chouaid, C."},{"role":"aut","family":"Bischoff","display":"Bischoff, Helge","roleDisplay":"VerfasserIn","given":"Helge"},{"display":"Reinmuth, N.","roleDisplay":"VerfasserIn","given":"N.","family":"Reinmuth","role":"aut"},{"family":"Cove-Smith","roleDisplay":"VerfasserIn","display":"Cove-Smith, L.","given":"L.","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","given":"T.","display":"Mansy, T.","family":"Mansy"},{"role":"aut","display":"Cortinovis, D. L.","roleDisplay":"VerfasserIn","given":"D. L.","family":"Cortinovis"},{"role":"aut","family":"Migliorino","given":"M. R.","roleDisplay":"VerfasserIn","display":"Migliorino, M. R."},{"family":"Delmonte","given":"A.","roleDisplay":"VerfasserIn","display":"Delmonte, A.","role":"aut"},{"role":"aut","family":"Garcia Sánchez","roleDisplay":"VerfasserIn","given":"J.","display":"Garcia Sánchez, J."},{"family":"Chara Velarde","given":"L. E.","roleDisplay":"VerfasserIn","display":"Chara Velarde, L. E.","role":"aut"},{"display":"Bernabe, R.","roleDisplay":"VerfasserIn","given":"R.","family":"Bernabe","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Paz-Ares, L.","given":"L.","family":"Paz-Ares"},{"family":"Chander","roleDisplay":"VerfasserIn","given":"P.","display":"Chander, P.","role":"aut"},{"role":"aut","given":"I.","roleDisplay":"VerfasserIn","display":"Diaz Perez, I.","family":"Diaz Perez"},{"role":"aut","family":"Foroutanpour","display":"Foroutanpour, K.","roleDisplay":"VerfasserIn","given":"K."},{"family":"Emeribe","roleDisplay":"VerfasserIn","given":"U.","display":"Emeribe, U.","role":"aut"},{"role":"aut","family":"Faivre-Finn","roleDisplay":"VerfasserIn","display":"Faivre-Finn, C.","given":"C."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["M.C. Garassino, J. Khalifa, M. Reck, C. Chouaid, H. Bischoff, N. Reinmuth, L. Cove-Smith, T. Mansy, D.L. Cortinovis, M.R. Migliorino, A. Delmonte, J. Garcia Sánchez, L.E. Chara Velarde, R. Bernabe, L. Paz-Ares, P. Chander, I. Diaz Perez, K. Foroutanpour, U. Emeribe & C. Faivre-Finn"]},"recId":"1936696878","id":{"eki":["1936696878"],"doi":["10.1016/j.esmoop.2025.105071"]},"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"9 S."}],"relHost":[{"disp":"Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer - final analysis from the phase II PACIFIC-6 trialESMO open","language":["eng"],"note":["Gesehen am 13.06.24"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"[London] ; London","dateIssuedDisp":"2016-","publisher":"Elsevier ; BMJ","dateIssuedKey":"2016"}],"corporate":[{"display":"European Society for Medical Oncology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"title":[{"title_sort":"ESMO open","subtitle":"cancer horizons","title":"ESMO open"}],"part":{"volume":"10","extent":"9","text":"10(2025), 6 vom: Juni, Artikel-ID 105071, Seite 1-9","issue":"6","year":"2025","pages":"1-9"},"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2016 -"],"name":{"displayForm":["European Society for Medical Oncology"]},"recId":"84705344X","id":{"issn":["2059-7029"],"eki":["84705344X"],"zdb":["2844985-X"]}}],"note":["Online verfügbar: 27. Mai 2025","Gesehen am 24.09.2025"],"origin":[{"dateIssuedDisp":"June 2025","dateIssuedKey":"2025"}]} | ||
| SRT | |a GARASSINOMDURVALUMAB2025 | ||